Show simple item record

dc.contributor.authorJones, RLen_US
dc.contributor.authorLe Cesne, Aen_US
dc.contributor.authorIbrahim, Ten_US
dc.contributor.authorGarcia Del Muro, Xen_US
dc.contributor.authorMenge, Fen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-11-14T09:04:17Z
dc.date.issued2018-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/30220224en_US
dc.identifier.citationExpert Rev Anticancer Ther, 2018, 18 (12), pp. 1241 - 1248en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2922
dc.identifier.eissn1744-8328en_US
dc.identifier.doi10.1080/14737140.2018.1524298en_US
dc.description.abstractINTRODUCTION: Health-related quality of life (HRQoL) is a patient-reported outcome that addresses patients' perceptions of symptoms across physical, emotional, cognitive and social domains. As HRQoL is currently rarely measured outside clinical trials in oncology, it must be inferred from patients' everyday performance during treatment. To gain insight into the HRQoL of advanced STS patients receiving palliative treatment in clinical practice, three case studies of patients treated with trabectedin are examined. Areas covered: The patient in Case 1 has maintained complete remission for more than 8 years after receiving nine cycles of second-line trabectedin followed by secondary surgery for recurrent myxoid liposarcoma, and was able to resume normal activities during trabectedin treatment. Case 2 describes 10 years' follow-up of a patient with myxoid liposarcoma who remains well after many lines of chemotherapy including extended use of trabectedin in the second line. The third case illustrates the feasibility of extending survival time in an elderly patient with metastatic leiomyosarcoma who was able to maintain a busy and active lifestyle while receiving second-line trabectedin. Expert commentary: Owing to its relatively benign safety profile, trabectedin frequently permits prolonged therapy and is generally well tolerated, often allowing patients to carry on with normal daily activities.en_US
dc.format.extent1241 - 1248en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.subjectHealth-related quality of lifeen_US
dc.subjectsoft tissue sarcomasen_US
dc.subjecttrabectedinen_US
dc.titlePreserving quality of life as a key treatment goal in advanced soft tissue sarcomas.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737140.2018.1524298en_US
rioxxterms.licenseref.startdate2018-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert Rev Anticancer Theren_US
pubs.issue12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume18en_US
pubs.embargo.termsNot knownen_US
icr.researchteamSarcoma Clinical Trials (R Jones)en_US
dc.contributor.icrauthorJones, Robinen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record